Don’t miss the latest developments in business and finance.

Home / Content / B2B Connect / Pharma / Glenmark receives US FDA nod for cholesterol-lowering drug fenofibrate

Glenmark receives US FDA nod for cholesterol-lowering drug fenofibrate

The approved product - fenofibrate capsule - is a generic version of AbbVie's Tricor capsule

Capsules; Image Courtesy: Siegfried
Premium
BS B2B Bureau Mumbai
Last Updated : Apr 11 2017 | 5:16 PM IST
Connect with us
Facebook IconLinkedIN Icon
Glenmark Pharmaceuticals has been granted final approval by the US Food & Drug Administration (FDA) for Fenofibrate capsule (67 mg, 134 mg and 200 mg). Fenofibrate, a drug of the fibrate class, is mainly used to reduce cholesterol levels in people at risk of cardiovascular disease. 

The approved product is the generic version of AbbVie Inc’s Tricor micronised capsule.

According to IMS Health sales data for the 12 month period ending February 2017, the Tricor micronised capsule (67 mg, 134 mg and 200 mg) market achieved annual sales of approximately $ 97.5 million.

Glenmark’s current portfolio consists of 114 products authorised for distribution in the US marketplace and approximately 64 ANDAs are pending approval with the US FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
Connect with us on WhatsApp

Also Read

Cipla receives US FDA's approval for generic Tricor tablet

Glenmark eyes big growth in US with cholesterol drug launch

Zydus settles patent litigation for cholesterol lowering drug with Kowa

Zydus receives US FDA approval for anti-viral drug oseltamivir

New drug that lowers cholesterol levels found

First Published: Apr 11 2017 | 4:14 PM IST

Explore News